News and Reports
-
Significant Investment Accelerates Freenome's Multiomics Platform for the Early Detection of Cancer
11 January 2022Download -
Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple Therapeutic Antibodies Using its Targeted Myeloid Engager and Phagocytosis Platform for the Treatment of Cancer
11 January 2022Download -
AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO IDENTIFY NOVEL RNA DEGRADER SMALL MOLECULE THERAPEUTICS
11 January 2022Download -
SWIXX SELECTED AS GILEAD’S BALTIC PARTNER
16 December 2021Download -
SWIXX SIGNS EXCLUSIVE DISTRIBUTION AGREEMENT WITH SANOFI FOR FOURTEEN CEE COUNTRIES
13 December 2021Download -
Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial
13 December 2021Download -
connectRN closes $76M financing to support accelerating growth of Healthcare Workforce Platform
8 December 2021Download -
Odyssey Therapeutics Announces $218 Million Series A Financing to Advance Next Generation Inflammation and Oncology Medicines
7 December 2021Download -
Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection
7 December 2021Download -
SWIXX SIGNS NEW ADDENDUM WITH JAZZ; ADDS VYXEOS® LIPOSOMAL FOR POLAND
3 December 2021Download -
NiKang Therapeutics Announces First Patient Dosed in A Phase 1
15 November 2021Download -
SK Biopharmaceuticals enters Greater China out-licensing 6 clinical pipelines to CNS-focused biotech Ignis Therapeutics
11 November 2021Download -
Acrivon Therapeutics Closes Oversubscribed $100 Million Series B Financing to Advance its Innovative Precision Proteomics Platform and Clinical Oncology Pipeline
11 November 2021Download -
SWIXX AND ALBIREO INK PAN-CEE AGREEMENT FOR BYLVAY®
4 November 2021Download -
IO Biotech, Inc. Announces Pricing of Initial Public Offering
4 November 2021Download -
Pyxis Announces Pricing of Upsized Initial Public Offering
8 October 2021Download -
IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial
14 September 2021Download -
Monte Rosa Therapeutics Announces Pricing of Initial Public Offering
24 June 2021Download -
Ambrx Announces Pricing of Initial Public Offering
18 June 2021Download -
Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing
20 May 2021Download -
Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR
4 May 2021Download -
Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering
30 April 2021Download -
Mineralys Therapeutics Closes $40 Million Series A Funding
6 April 2021Download -
Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics
30 March 2021Download -
IPOs of Instil Bio and Connect Biopharma increase net asset value per HBM share by CHF 4.55 (+1.5%)
22 March 2021Download